Regency Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-1,000
Closed -$52K 72
2022
Q2
$52K Hold
1,000
0.06% 56
2022
Q1
$52K Sell
1,000
-112
-10% -$5.81K 0.04% 70
2021
Q4
$66K Sell
1,112
-234
-17% -$11.6K 0.04% 73
2021
Q3
$58K Hold
1,346
0.04% 84
2021
Q2
$53K Sell
1,346
-611
-31% -$23.8K 0.04% 79
2021
Q1
$71K Buy
+1,957
New +$69.5K 0.07% 85

Other funds holding PFE

Regency Capital Management's PFE Position: Q3 2022 in Review

Regency Capital Management sold out of Pfizer (PFE) in Q3 2022, closing a stake of 1,000 shares — an estimated $52K sold.

Regency Capital Management first reported a position in PFE in Q1 2021 and held it in 6 quarters. The position peaked at $71K in Q1 2021. 3,085 funds tracked by Wall St. Rank hold PFE as of Q3 2022.

  • Regency Capital Management reported no remaining Pfizer position as of Q3 2022 after selling out during the quarter.
  • Regency Capital Management sold 1,000 Pfizer shares in Q3 2022, an estimated $52K.
  • Regency Capital Management first reported a position in Pfizer in Q1 2021 and held it in 6 quarters.
  • Regency Capital Management's Pfizer position peaked at $71K in Q1 2021.
  • 3,085 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.

Based on Regency Capital Management's 13F filing for Q3 2022, filed 4 Nov 2022.